IP Library Granted Patent US 10,604,565
Granted Patent B2
US 10,604,565 · App. 15/912,358 · Granted Mar 31, 2020

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

Inventors: Jörg Wischhusen (Würzburg, DE); Markus Junker (Würzburg, DE); Tina Schäfer (Würzburg, DE); Dirk Pühringer (Rimpar, DE)
Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
C07K16/22A61K2039/505C07K2317/24C07K2317/34C07K2317/565C07K2317/73C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,604,565
App. No.
15/912,358
Granted
Mar 31, 2020
Kind
B2
Abstract

The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Claims (18)

1. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising: a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 28; and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 31.

2. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 28.

3. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 31.

4. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising: a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 27; and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 30.

5. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 27.

6. A monoclonal antibody that specifically binds to human GDF-15, or an antigen-binding portion thereof, comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 30.

7. The monoclonal antibody or antigen-binding portion thereof of claim 1 , comprising a human heavy chain constant region.

8. The monoclonal antibody or antigen-binding portion thereof of claim 1 , comprising a human IgG1 or IgG4 heavy chain constant region.

9. The monoclonal antibody or antigen-binding portion thereof of claim 1 , comprising a human light chain constant region.

10. The monoclonal antibody or antigen-binding portion thereof of claim 1 , comprising a human kappa light chain constant region.

11. A pharmaceutical composition comprising the antibody or antigen-binding portion thereof of claim 1 .

12. A pharmaceutical composition comprising the antibody or antigen-binding portion thereof of claim 4 .

13. A nucleotide sequence encoding the heavy chain variable domain and/or the light chain variable domain of the antibody of claim 1 .

14. An expression vector comprising the nucleotide sequence of claim 13 .

15. A cell line comprising the expression vector of claim 14 .

16. A nucleotide sequence encoding the heavy chain and/or the light chain of the antibody of claim 4 .

17. An expression vector comprising the nucleotide sequence of claim 16 .

18. A cell line comprising the expression vector of claim 17 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: WISCHHUSEN, JÖRG; JUNKER, MARKUS; SCHÄFER, TINA; PÜHRINGER, DIRK
To: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
Reel/Frame 051854/0898 →
Priority Claims (2)
GB 1405475.3 · Mar 26, 2014 · national
GB 1405477.9 · Mar 26, 2014 · national
Continuity (2)
Continuation 15128604
Related Publication 20180298091A1 · Oct 18, 2018
Cited By (3)
US 12,473,354 US 12,497,447 US 12,629,418